Open an account

Aethlon Medical

AEMD · NASDAQ

$5.31+$0.15 (+2.91%)TodayMarket closed ·
Prev close $5.16

About AEMD

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The firm is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.

Employees
9
Headquarters
San Diego, California
Listed
Mar 9, 1994
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
aethlonmedical.com

AEMD key statistics

Market cap
8.52M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
151.31K
Volume
36.49K
Open price
$5.16
High today
$5.47
Low today
$5.12
52 Week high
$29.45
52 Week low
$1.41

Aethlon Medical (AEMD) at a glance

Aethlon Medical (AEMD) last traded at $5.31, with a market cap of 8.52M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.12 and $5.47. The current price is 3.8% above the day's low and 2.9% below its high.

Volume so far is 36.49K shares, below the average of 151.31K shares a day.

Over the past year Aethlon Medical has ranged from $1.41 to $29.45, and now sits 14% of the way up that range.

Aethlon Medical met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q1 FY27 it reported -$4.02 per share against an estimate of -$0.8007.

AEMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 17.9% on average.

  1. Q2 FY25: reported -$16.00 per share against an estimate of -$15.91
  2. Q3 FY25: reported -$10.40 per share against an estimate of -$17.41
  3. Q4 FY25: reported -$79.70 per share against an estimate of -$10.30
  4. Q1 FY26: reported -$8.50 per share against an estimate of -$8.77
  5. Q2 FY26: reported -$3.74 per share against an estimate of -$3.74
  6. Q3 FY26: reported -$2.45 per share against an estimate of -$2.47
  7. Q4 FY26: reported -$1.49 per share against an estimate of -$2.06
  8. Q1 FY27: reported -$4.02 per share against an estimate of -$0.8007

AEMD news

  • Press releasePRNewswire

    Are PRTH, MG, AEMD Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)

  • Evette Mitkov

    Aethlon Stock Pulls Back: What's Going On?

  • Aethlon Medical Q1 2027 Earnings Call Transcript

  • Shivdeep Dhaliwal

    Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today

  • Avi Kapoor

    Crude Oil Down 1%; US Pending Home Sales Rise 0.3% In August

  • Avi Kapoor

    Nasdaq Jumps 400 Points; US Weekly Jobless Claims Fall

  • Press releaseGlobe Newswire

    Four High-Impact Small Caps Enter the Spotlight

Similar companies

Companies in the same industry as Aethlon Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.